Spots Global Cancer Trial Database for blood protein disorders
Every month we try and update this database with for blood protein disorders cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | NCT05280275 | Multiple Myelom... Neoplasms Neoplasms, Plas... Gammopathy, Mon... Paraproteinemia... Blood Protein D... Haematologic Di... Corneal Disease | Belantamab Mafo... Daratumumab Lenalidomide Dexamethasone | 18 Years - | Hellenic Society of Hematology | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | NCT04309084 | Multiple Myelom... Neoplasm, Plasm... Neoplasms by Hi... Neoplasms Hemostatic Diso... Vascular Diseas... Cardiovascular ... Paraproteinemia... Blood Protein D... Hematologic Dis... Hemorrhagic Dis... Lymphoprolifera... Immunoprolifera... Immune System D... Antineoplastic ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... Physiological E... | CYNK-001 | 18 Years - 75 Years | Celularity Incorporated | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | NCT05228470 | Elranatamab Myeloma Multiple Myelom... Relapsed Multip... Refractory Mult... PF-06863135 BCMA Bispecific Bispecific Anti... BCMA-CD3 Bispec... MagnetisMM-8 | Elranatamab | 18 Years - | Pfizer | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia | NCT02952508 | Waldenstrom Mac... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... Mantle Cell Lym... Diffuse Large B... Central Nervous... | Iopofosine I 13... Iopofosine I 13... Iopofosine I 13... | 18 Years - | Cellectar Biosciences, Inc. | |
| A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment | NCT05147493 | Multiple Myelom... Renal Impairmen... Neoplasms, Plas... Neoplasms by Hi... Neoplasms Paraproteinemia... Blood Protein D... Hematologic Dis... | Isatuximab Bortezomib Cyclophosphamid... Dexamethasone Lenalidomide | 18 Years - | Hellenic Society of Hematology | |
| Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | NCT01183949 | Multiple Myelom... | AT7519M Bortezomib | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma | NCT02155634 | Multiple Myelom... Neoplasms Plasma Cells Paraproteinemia... Blood Protein D... Hematologic Dis... Therapeutic Use... | Lenalidomide | 18 Years - | Celgene | |
| A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | NCT05280275 | Multiple Myelom... Neoplasms Neoplasms, Plas... Gammopathy, Mon... Paraproteinemia... Blood Protein D... Haematologic Di... Corneal Disease | Belantamab Mafo... Daratumumab Lenalidomide Dexamethasone | 18 Years - | Hellenic Society of Hematology | |
| A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma | NCT01063907 | Multiple Myelom... | KW-2478 Bortezomib | 18 Years - | Kyowa Kirin Co., Ltd. | |
| A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor | NCT05298683 | Multiple Myelom... Renal Impairmen... Neoplasms, Plas... Neoplasms by Hi... Neoplasms Paraproteinemia... Blood Protein D... Hematologic Dis... | Isatuximab Pomalidomide Dexamethasone Acetaminophen (... Ranitidine (or ... Diphenhydramine... | 18 Years - | Hellenic Society of Hematology | |
| Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia | NCT02952508 | Waldenstrom Mac... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... Mantle Cell Lym... Diffuse Large B... Central Nervous... | Iopofosine I 13... Iopofosine I 13... Iopofosine I 13... | 18 Years - | Cellectar Biosciences, Inc. | |
| Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) | NCT00773747 | Multiple Myelom... | Vorinostat bortezomib placebo to vori... | 18 Years - | Merck Sharp & Dohme LLC | |
| ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma | NCT01997840 | Multiple Myelom... | ACY-1215 (Ricol... | 18 Years - | Celgene | |
| A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory | NCT05581875 | Multiple Myelom... Multiple Myelom... Neoplasms Gammopathy, Mon... Paraproteinemia... Blood Protein D... Haematologic Di... Corneal Disease Neoplasms, Plas... | Belantamab Mafo... Daratumumab Pomalidomide Dexamethasone | 18 Years - | Hellenic Society of Hematology | |
| A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | NCT05280275 | Multiple Myelom... Neoplasms Neoplasms, Plas... Gammopathy, Mon... Paraproteinemia... Blood Protein D... Haematologic Di... Corneal Disease | Belantamab Mafo... Daratumumab Lenalidomide Dexamethasone | 18 Years - | Hellenic Society of Hematology | |
| Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | NCT01183949 | Multiple Myelom... | AT7519M Bortezomib | 18 Years - | Astex Pharmaceuticals, Inc. | |
| ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma | NCT01997840 | Multiple Myelom... | ACY-1215 (Ricol... | 18 Years - | Celgene |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
